Biotech

All Articles

Acelyrin goes down izokibep, lets go 3rd of workers

.Even with izokibep keeping its newly found winning streak in the facility, Acelyrin is no longer co...

Rivus' phase 2 obesity-related heart failure test attacks endpoint

.Rivus Pharmaceuticals has actually plumped up the leads of its own fat-busting, muscle-sparing medi...

Ovid stops preclinical job, IV course after soticlestat fall short

.Ovid Therapeutics presently showed final month that it was actually trimming its own headcount as t...

Eli Lilly opens $700M nucleic acid R&ampD facility in Boston ma Port

.Eli Lilly has opened a $700 thousand R&ampD facility in the Boston Port, boosting its RNA and DNA r...

Boundless Biography makes 'small' cutbacks 5 months after $100M IPO

.Merely five months after protecting a $100 million IPO, Boundless Biography is actually presently g...

Halda's $126M will certainly progress 'hold and kill' growth medications

.The preliminary stages of oncology R&ampD may not be short of interesting new modalities, and Halda...

Lykos 'regrets' certainly not divulging research infractions with publisher

.Psychopharmacology has pulled 3 posts about midstage scientific trial information examining Lykos R...

Analysts dig into Avidity's DMD succeed, uncovering distinctions in information

.Avidity Biosciences pleased clients with phase 1/2 data in Duchenne muscle dystrophy (DMD) Friday, ...

Actinogen's cortisol blocker fails period 2 depression research

.Actinogen Medical's cortisol blocker has overlooked the primary endpoint of a stage 2 research in c...

Bivictrix chooses going exclusive only means to take ADC right into clinic

.Antibody-drug conjugates (ADCs) have gone to the center of lots of a billion-dollar biobuck licensi...